Cidara Therapeutics To Present New Preclinical Data On Novel Dual-Acting Drug-Fc Conjugates At ESMO Immuno-Oncology Annual Congress
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics, Inc. (NASDAQ:CDTX) will present new preclinical data on its novel drug-Fc conjugate (DFC) immunotherapies at the ESMO Immuno-Oncology Congress. The presentations will cover a dual-acting CD73/PD-1 targeting DFC candidate and CBO421, a first-in-class CD73 targeting DFC. The event is scheduled for December 6-8, 2023.
November 30, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cidara Therapeutics is set to present new preclinical data on its DFC immunotherapies, which could positively influence investor perception and potentially the stock price if the data is promising.
The presentation of new preclinical data at a significant conference like ESMO IO can be a positive catalyst for Cidara Therapeutics' stock as it may signal progress in their drug development pipeline. Positive data can lead to increased investor confidence and anticipation of future success in clinical trials, which can drive the stock price up in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100